BioSante Will Merge With ANI Pharma in Stock Deal

NEW YORK (AP) — BioSante Pharmaceuticals  (Nasdaq: BPAX  ) said Thursday it will merge with ANI Pharmaceuticals in an all-stock deal worth about $94 million.

BioSante has spent years developing LibiGel, a testosterone gel intended to treat sexual dysfunction in women, but has not been able to gain approval because of study failures and safety concerns. ANI markets branded and generic drugs and provides contract drug manufacturing services, and it had about $16 million in revenue in 2011. The companies said the deal combines BioSante's cash and expected revenue from licensing deals with ANI's current revenue.

BioSante valued the deal at $93 million to $95 million based on its current share price, according to a company spokesman. In midday trading its shares lost 19 cents to $1.61.

The boards of both companies have approved the deal and said it should close in the first quarter of 2013. The combined company will take BioSante's corporate structure but will change its name to ANI Pharmaceuticals. Current ANI shareholders will own 53 percent of the new company, and Arthur Przybyl of ANI will be its president and CEO. The board will include four other ANI directors and two BioSante directors.

BioSante, based in Lincolnshire, Ill., reported about $223,000 in revenue in the first half of 2012, and the company said ANI's revenue will help support development of more costly products. That includes several experimental cancer treatments as well as LibiGel.

Shares of BioSante have fallen 88 percent since mid-December, when the company said LibiGel failed in two late-stage clinical trials. In September the company reported positive data from safety studies, saying clinical testing did not reveal links between LibiGel and heart attack or breast cancer. BioSante plans to ask the FDA to approve two new late-stage trials of LibiGel in early 2013.

ANI is based in Baudette, Minn., and its approved products include generic versions of the obsessive compulsive disorder treatment Luvox, the hormone replacement drug Estratest, and Reglan, a drug used to treat slow stomach emptying in diabetes patients.

BioSante helped develop the hot flash treatment Elestrin, which is marketing by Jazz Pharmaceuticals PLC. Early this year, the Food and Drug Administration approved a testosterone gel that BioSante developed. Bio-T-Gel will be marketed by Teva Pharmaceutical Industries Ltd. However, no launch date for the product has been announced.

BioSante said it will distribute contingent value rights worth up to $40 million to its shareholders before the deal closes. Those rights mean shareholders will receive payments from future sales, licenses, or other deals involving LibiGel.

The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2044332, ~/Articles/ArticleHandler.aspx, 11/28/2014 5:15:46 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement